Monocyte heterogeneity and functions in cancer.
Olingy CE, Dinh HQ, Hedrick CC. · 2019
Read Monocyte heterogeneity and functions in cancer. by Olingy CE, Dinh HQ, Hedrick CC. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6658332.txt.
Introduction
Olingy and co-authors review monocyte diversity and its functions in cancer. Their review appears in the Journal of Leukocyte Biology. Monocytes were once viewed as one uniform cell type. They actually split into distinct subsets. Classical, intermediate, and nonclassical groups are now standard. In cancer these subsets pull in opposite directions. Some kill tumour cells and rally lymphocytes. Others feed blood vessel growth and matrix remodelling. Monocytes also seed tumour-associated macrophages and dendritic cells.
Which signals dominate decides the net effect. The review covers subset behaviour during steady state first. It then details their cancer progression roles. Closing sections describe monocyte-targeted treatment strategies. Better subset control could sharpen immunotherapy.
Catalog record
| CREATOR | Olingy CE, Dinh HQ, Hedrick CC. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 82 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Monocyte heterogeneity and functions in cancer By Claire E Olingy, Huy Q Dinh, Catherine C Hedrick Published in: Journal of Leukocyte Biology DOI: 10.1002/JLB.4RI0818-311R ABSTRACT Abstract Monocytes are innate immune cells of the mononuclear phagocyte system that have emerged as important regulators of cancer development and progression. Our understanding of monocytes has advanced from viewing these cells as a homogenous population to a heterogeneous system of cells that display diverse responses to different stimuli. During cancer, different monocyte subsets perform functions that contribute to both pro‐ and antitumoral immunity, including phagocytosis, secretion of tumoricidal mediators, promotion of angiogenesis, remodeling of the extracellular matrix, recruitment of lymphocytes, and differentiation into tumor‐associated macrophages and dendritic cells. The ability of cancer to evade immune recognition and clearance requires protumoral signals to outweigh ongoing attempts by the host immune system to prevent tumor growth. This review discusses current understanding of monocyte heterogeneity during homeostasis, highlights monocyte functions in cancer progression, and describes monocyte‐targeted therapeutic strategies for cancer treatment. Keywords: Monocytes, cancer, tumor microenvironment, myeloid cells AbbreviationsCARchimeric Ag receptorcMoPcommon monocyte progenitorDCdendritic cellECMextracellular matrixFlt3fms related tyrosine kinase 3GMPgranulocyte‐macrophage progenitorHIFhypoxia‐inducible factorLFA‐1lymphocyte function‐associated antigen 1MDPMϕ‐DC progenitorMHCIIMHC class IIM‐MDSCMonocytic myeloid‐derived suppressor cellMMPmatrix metalloproteinasemoDCmonocyte‐derived DCscRNA‐Seqsingle cell RNA sequencingTregRegulatory T cellTAMtumor‐associated MϕVEGFvascular endothelial growth factor Monocytes are mononuclear phagocytes that comprise a major population of innate immune cells that circulate in the bloodstream and traffic to tissues during steady state and at increased rates during inflammation. These cells play key roles in supporting tissue homeostasis, initiating and propagating host responses to pathogens, and resolving immune responses before excessive tissue damage occurs.1 Recently, monocytes have emerged as important regulators of cancer development and progression, with different subsets appearing to have opposing roles in enabling tumor growth2 and preventing metastatic spread of cancerous cells.3 Monocytes also serve as a primary source of long‐lived tumor‐associated Mϕs (TAMs) and dendritic cells (DCs) that shape the tumor microenvironment.4 An understanding of monocyte heterogeneity and roles at different stages of cancer progression is critical for improving our understanding of cancer's ability to evade the immune system and ultimately to design novel therapies to enhance antitumoral immunity. In this review, we summarize current work that has explored monocyte heterogeneity and function in the context of cancer and highlight key strategies that leverage monocytes for improving cancer therapies. MONOCYTE HETEROGENEITY Over the last 40 years, our understanding of monocytes has progressed from viewing these cells as a homogenous population to a heterogeneous system of cells that display diverse functions in response to different stimuli. Human monocytes universally express the MHC class II (MHCII) receptor HLA‐DR, integrin αM (CD11b), and CD86, while murine monocytes express CSF1 receptor (CSF1R, CD115), CD11b, and FcγRI (CD64). Currently, 3 subsets of monocytes have been established: classical monocytes (CD14+CD16– in human, Ly6ChiCD43loCX3CR1lo in mouse), nonclassical monocytes (CD14loCD16+ in human, Ly6CloCD43hiCX3CR1hi in mouse), and intermediate monocytes (CD14+CD16+ in human, Ly6CintCD43hiCX3CR1hi in mouse).5 This long‐standing nomenclature was first defined in the late 1980s using 2‐color flow cytometric detection of CD14 and CD16 Ags on human PBMCs.6 Whether multiple monocyte subsets were also present in mice remained unclear until the early 2000s. The first evidence that murine monocytes were also composed of distinct subsets emerged in work that identified 2 populations with different patterns of CX3CR1, CCR2, and CD62L expression.7 Two years later, a landmark study confirmed the presence of CX3CR1hi and CX3CR1lo monocyte subsets with significant differences in chemokine receptor expression, adhesion molecule profiles, and trafficking within homeostatic and inflamed tissue.8 While these initial studies relied on engineered mice with green fluorescent protein inserted into the Cx3cr1 locus, subsequent studies have identified Ly6C as a more specific marker for discrimination of circulating monocyte subsets and reinforced previously reported phenotypic differences.9, 10, 11 Human monocyte subsets were also found to display differential expression of CX3CR1 that corresponded with similar phenotypes to those observed in mouse, suggesting that mouse and human monocyte subsets may share similarities.8 Genome‐wide transcriptome profiling10 and adoptive transfer assays to assess patrolling and response to inflammatory stimuli in immunocompromised mice12 later reinforced that classical and nonclassical monocytes in mouse and human are counterparts. Additional surface markers have been useful for improving discrimination of monocyte subsets. We recently used mass cytometry (CyTOF) to demonstrate that inclusion of HLA‐DR, CCR2, CD36, and CD11c markers substantially increases the gating purity of human monocyte subsets, particularly CD14+CD16+ intermediate monocytes.13 Ly6C, MHCII, CD43, and Treml4 have enabled better identification of murine monocyte subsets, particularly within tissues where Ly6Chi monocytes can down‐regulate Ly6C, but maintain low expression of CD43 and Treml4.14 High expression of Treml4 is also useful for discrimination of intermediate monocytes from Ly6Chi and Ly6Clo populations.15 The numbers of these markers will likely continue to expand as high‐dimensional techniques are used to further profile monocyte transcriptional and proteomic states. Single‐cell transcriptional profiling has challenged our understanding of heterogeneity within well‐established immune populations and monocytes are no exception. Deep single cell RNA sequencing (scRNA‐Seq) using Smart‐Seq2 recently revealed 2 novel human monocyte subsets.16 While most (about 70%) of CD14+C16+ monocytes typically classified in the intermediate subset fell within classical (Mono1) and nonclassical (Mono2) monocyte clusters, the remaining CD14+CD16+ cells formed 2 new rare clusters termed Mono3 and Mono4 (12% of total monocytes). Mono3 highly expresses genes associated with cell cycle, differentiation, and trafficking, while Mono4 expresses high levels of cytotoxic gene signatures including NK and T cell activation genes. To date, no additional studies have validated the existence of these novel subsets, developed methodologies to isolate Mono3 and Mono4, or sought to identify their function. In mice, scRNA‐Seq revealed that monocytes primarily cluster into 4 types, 2 of which overlap with conventionally defined classical Ly6Chi monocytes and nonclassical Ly6Clo monocytes.11 The other 2 monocyte clusters were primarily Ly6Cint monocytes with 1 subset showing intermediate expression of classical monocyte genes and the other expressing MHCII‐associated genes and CD209a. The CD209a‐expressing subset is likely similar to the previously identified subset of Ly6C+ monocytes that express DC‐related genes, including those encoding CD209a, fms related tyrosine kinase 3 (Flt3, CD135), and MHCII, and give rise to DCs following exposure to GM‐CSF.17 Although additional studies are needed to confirm and understand the functional roles of new monocyte subsets, these studies indicate that conventional definitions of monocyte subsets will likely be modified and expanded, particularly within the intermediate subset. MONOCYTE DEVELOPMENTAL ORIGINS AND FATES Understanding the origin and fates of monocytes is crucial to understanding how these cells respond in cancer settings. Monocytes circulate in peripheral blood during steady state after developing from a lineage‐committed bone marrow progenitor, the common monocyte progenitor (cMoP), which was first discovered in mouse.18 The human cMoP was recently identified in human umbilical cord blood and bone marrow.19 In both mouse and human, cMoPs are unipotent monocyte progenitors that express the stem cell marker CD117, as well as the C‐type lectin CLEC12A and CD64. In contrast to mouse cMoPs, human cMoPs express CD135, a cytokine receptor and early hematopoietic marker. Monocyte development is regulated by sequential expression of key transcription factors in the following order: PU.1, IRF8, and KLF4, which has been reviewed previously by our group.20 PU.1 (encoded by Spi1) is a master regulator that is required for development of all myeloid cells and regulates expression of downstream factors such